European Companies Search Engine
Elicio Therapeutics Inc., Boston, United States
Watch
If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.
Dossier
The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .
Add to dossier (if available):
Name
Elicio Therapeutics Inc.
Identification
Stockp
ELTX
Address
Corporate purpose
2834
Pharmaceutical Preparations
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the … Show more
History
Network
Loading network
Annual report
Publications
7 May 2025
There are no publications matching your search.
The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.
The visualizations for "Elicio Therapeutics Inc., Boston, United States"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
